Screening for Substance Use Disorders/Opioid Use Disorder

Provides examples of patient behaviors that may indicate prescription medication abuse or addiction and behaviors that may appear aberrant but are likely to be part of the normal process of stabilizing a patient's pain condition.

Provides guidance on the use of buprenorphine among a number of topics, including physiology and pharmacology of opioids, opioid addiction, and buprenorphine treatment; screening and assessment of OUDs; protocols for buprenorphine treatment; management of special populations; and policies and procedures related to DATA 2000.

Helps clinicians better identify the presence of opioid abuse or dependence in patients with chronic pain.

Uses a 20-item instrument administered in an interview format to track behaviors characteristic of addiction related to prescription opioid medications in chronic pain populations. The instrument is scored based on participant responses, interviewer observations of displayed behaviors, and information gathered from medical chart review.

Provides a score indicating the severity of dependence on opioids using a 5-item questionnaire.

Uses a 17-item self-assessment to identify patients with chronic pain taking opioids who have indicators of current aberrant drug-related behaviors.

Assesses the risk of opioid abuse and suitability of candidates for long-term opioid therapy in primary care.

Guides physicians to incorporate screening, brief interventions, and referrals to treatment for use of alcohol, tobacco, marijuana, and other drugs among adolescent patients.

Details a checklist for providers to use when determining if a patient meets the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria for a diagnosis of opioid use disorder.

Reviews three FDA-approved medications for OUD treatment (methadone, naltrexone, and buprenorphine) and the other strategies and services needed to support people in recovery.